BBIONasdaqPharmaceutical PreparationsFiscal year ends December 31

BridgeBio Pharma, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026

$67.94+1.55 (+2.33%)

Close on Oct 19, 2026

Market cap: $13.30B
P/E (TTM): –
Dividend yield: –

BridgeBio Pharma, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31
Revenue	502	222	9.30	78	70	8.25	41	–	–
Cost of Revenue	21	3.88	2.45	3.43	3.11	–	–	–	–
Gross Profit	481	218	6.86	74	67	–	–	–	–
Research & Development	452	506	456	399	451	337	210	140	31
Selling, General & Admin	531	289	151	143	192	146	94	–	–
General & Administrative	–	–	–	–	–	146	94	44	13
Advertising Expenses	110	22	0	–	–	–	–	–	–
Operating Expenses	–	–	–	–	–	483	307	184	44
Total Costs & Expenses	1,025	815	617	590	646	483	307	–	–
Operating Income	-523	-593	-607	-512	-577	-474	-266	-184	-44
Interest Expense	53	91	81	80	47	37	8.77	2.55	0.01
Interest & Investment Income	20	17	18	7.54	1.13	4.02	8.92	2.00	0.04
Income from Equity Investments	-73	-31	0	0	–	–	-21	-0.28	–
Other Non-Operating Income	-209	51	-46	28	-9.82	-31	-22	14	0.03
Merger & Restructuring Charges	21	16	7.93	44	0	0	–	–	–
Asset Impairment Charges	0	0.27	0	13	0	0	0	–	–
Gain (Loss) on Investments	0	8.14	18	-8.22	30	0	0	–	–
Gain (Loss) on Sale of Assets	–	0	0	-6.26	0	0	–	–	–
Pretax Income	-733	-542	-653	-485	–	505	289	169	44
Income Tax Expense	0.44	1.15	0	0	–	–	–	–	–
Net Income incl. Noncontrolling Interests	-733	-543	-653	-485	-586	-505	-289	-169	-44
Minority Interest in Earnings	-8.01	-7.59	-10	-3.47	-24	-57	-28	-39	-13
Net Income to Common	-725	-536	-643	-481	-563	-449	-261	-131	-31
EPS (Basic)(per share)	-3.78	-2.88	-3.95	-3.26	-3.90	-3.80	-2.48	-2.12	-1.00
EPS (Diluted)(per share)	-3.78	-2.88	-3.95	-3.26	-3.90	-3.80	-2.48	-2.12	-1.00
Shares Outstanding (Basic, Weighted)(shares)	192	186	163	147	144	118	105	62	31
Shares Outstanding (Diluted, Weighted)(shares)	192	186	163	147	144	118	105	62	31
EBITDA	-518	-587	-601	-505	-571	-473	-265	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 94.4%
Operating margin: -69.8%
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 1.23
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 76.1%

Valuation

P/E ratio: –
Price to sales: 18.65
Price to book: –
Dividend yield: –